Postoperative Anxiety and Depression
Conditions
Interventions
Intervention Group:Esketamine (0.25 mg/kg) will be administered intravenously at anesthesia induction, followed by a second dose (0.125 mg/kg) 30 minutes before the end of surgery.
Control Group:The control group will receive a placebo (normal saline) at the same time points. The placebo will be matched to the esketamine formulation in appearance, volume, and route of administra
Sponsors
Tongji University School of medicine, Shanghai East Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. 12 years < Age < 18 years; 2. American Society of Anesthesiologists (ASA) physical status I or II; 3. No significant congenital systemic diseases; 4. No known allergy to esketamine or its excipients; 5. Willing to participate and provide written informed assent (by the participant) and consent (by a parent or legal guardian).
Exclusion criteria
Exclusion criteria: 1. History of severe psychiatric or neurological disorders that would impair cooperation; 2. Significant congenital diseases affecting major organs (e.g., heart, lung, brain, kidney) ; 3. Presence of active respiratory tract infection within recent weeks (e.g., 2-4 weeks prior to surgery) ; 4. Known hypersensitivity or allergy to esketamine or its excipients; 5. Pre-existing diagnosis of anxiety or depression requiring pharmacological treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative Anxiety ;Postoperative Depression; | — |
Secondary
| Measure | Time frame |
|---|---|
| Opioid use;VAS score;adverse reaction; | — |
Countries
China
Contacts
Public ContactZhonghua Ji
Tongji University School of medicine, Shanghai East Hospital
Outcome results
None listed